Massachusetts General Hospital, Department of Medicine, Boston, MA.
Division of Population Sciences, Dana Farber Cancer Institute, Boston, MA.
Health Serv Res. 2018 Aug;53(4):2118-2132. doi: 10.1111/1475-6773.12745. Epub 2017 Jul 26.
To characterize spending patterns for Medicare patients with incident breast, prostate, lung, and colorectal cancer.
DATA SOURCES/STUDY SETTING/STUDY DESIGN: 2007-2012 data from the Surveillance, Epidemiology, and End Results Program linked with Medicare fee-for-service claims.
DATA COLLECTION/EXTRACTION METHODS: We calculate per-patient monthly and yearly mean and median expenditures, by cancer type, stage at diagnosis, and spending category, over the years of diagnosis and death.
Over the year of diagnosis, mean spending was $35,849, $26,295, $55,597, and $63,063 for breast, prostate, lung, and colorectal cancer, respectively. Over the year of death, spending was similar across different cancer types and stage at diagnosis.
Characterization of Medicare spending according to clinically meaningful categories may assist development of oncology alternative payment models and cost-effectiveness models.
描述医疗保险患者中乳腺癌、前列腺癌、肺癌和结直肠癌患者的支出模式。
数据来源/研究设置/研究设计：2007 年至 2012 年来自监测、流行病学和最终结果计划的数据，与医疗保险按服务收费的索赔相联系。
数据收集/提取方法：我们按癌症类型、诊断时的阶段和支出类别，计算诊断和死亡年份的每位患者每月和每年的平均和中位数支出。
在诊断年度内，乳腺癌、前列腺癌、肺癌和结直肠癌的平均支出分别为 35849 美元、26295 美元、55597 美元和 63063 美元。在死亡年度内，不同癌症类型和诊断时的阶段的支出相似。
根据有临床意义的类别对医疗保险支出进行描述，可能有助于制定肿瘤学替代支付模式和成本效益模型。
